Background: Amiodarone (AMIO) is for many years effectively used to control ventricular rate during atrial fibrillation (AF) and to convert it into sinus rhythm. However, due to its delayed onset of action, ranolazine (RAN), a new antianginal agent with atrial-selective electrophysiologic properties, has recently been attempted as add-on therapy with AMIO to facilitate AF conversion.
Methods: To establish the role of this combination therapy, we enrolled 173 consecutive patients (68 ± 10 years, 54% male) with recent-onset (<48-hour duration) AF who were eligible for pharmacologic cardioversion. Patients were randomized to intravenous AMIO (loading dose 5 mg/kg in 1 hour followed by 50 mg/h; n = 81), or AMIO plus a single oral dose of RAN 1 g (n = 92).
Results: Mean left atrial diameter did not significantly differ between groups, AMIO and AMIO + RAN (4.2 ± 0.5 cm vs 4.1 ± 0.4 cm, P = 0.18). The AMIO + RAN group compared with the AMIO-only group showed significantly shorter time to conversion (8.6 ± 2.8 hours vs 19.4 ± 4.4 hours, P < 0.0001) and higher conversion rate at 24 hours (98% vs 58%, P < 0.001). Left ventricular ejection fraction did not markedly vary between the two groups and ranged within moderately reduced values. No serious clinically evident adverse effects were observed in any of the patients receiving either AMIO or the combination treatment.
Conclusions: Our data demonstrate faster sinus rhythm restoration and enhanced conversion rate of AF after AMIO plus RAN in patients with preserved ejection fraction and left atrial size, implicating a synergistic effect of the two agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pace.13048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence, Mechanism, and Management of Atrial Ablation Procedure Complications: A Literature Review.
Cardiol Rev
December 2024
Departments of Cardiology and Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY.
The number of atrial catheter ablation procedures has significantly increased in recent years, becoming a first-line treatment modality for various supraventricular tachycardias due to their safety and efficacy. Complications, ranging from mild to life-threatening, can arise during different stages of the procedure, including vascular access complications (eg, hematoma or vascular fistula formation, retroperitoneal bleeding, etc.), thromboembolic complications (eg, stroke, transient ischemic attack, air embolism, etc.
View Article and Find Full Text PDFImpact of leadless pacemaker implantation site on cardiac synchronization and tricuspid regurgitation.
Egypt Heart J
January 2025
Department of Cardiology, Hangzhou First People's Hospital, #261 Huansha Road, Hangzhou, 310000, Zhejiang Province, China.
Background: To investigate the optimization of leadless pacemaker placement and to assess its impact on heart synchronization and tricuspid regurgitation.
Results: A clinical trial was conducted involving 53 patients who underwent leadless pacemaker implantation at the Second Affiliated Hospital of Zhejiang University School of Medicine and Hangzhou First People's Hospital between March 2022 and February 2023. Implantation site localization was determined using the 18-segment method under RAO 30° imaging.
Risk and Protective Factors of Poor Clinical Outcomes in Heart Failure with Improved Ejection Fraction Population: A Systematic Review and Meta-Analysis.
Curr Cardiol Rep
January 2025
Faculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Aims: Heart failure with improved ejection fraction (HFimpEF) patients could still develop adverse outcomes despite EF improvement. This study evaluates the risk and protective factors of poor clinical outcomes in HFimpEF patients.
Methods: Systematic searching was done to include studies that evaluate the risks of developing poor outcomes in HFimpEF patients.
Inappropriate antithrombotic use in geriatric patients with complicated traumatic brain injury.
J Trauma Acute Care Surg
January 2025
From the Spencer Fox Eccles School of Medicine (D.G., J.A.), Department of Neurosurgery (D.B., M.T.B., S.T.M., R.G.), Department of Surgery (S.L., J.C., M.M., T.E.), Division of Geriatrics and Department of Internal Medicine (M.P.), University of Utah, Salt Lake City, Utah; and Bowers Neurosurgical Frailty and Outcomes Data Science Lab (C.A.B.), Flint, Michigan.
Background: Preinjury antithrombotic (AT) use is associated with worse outcomes for geriatric (65 years or older) patients with traumatic brain injury (TBI). Previous studies have found that use of AT outside established guidelines is widespread in TBI patients.
Methods: In this single-center retrospective cross-sectional study, we examined inappropriate AT use among geriatric patients presenting with traumatic intracranial hemorrhage.
Real-world antithrombotic strategies in patients with atrial fibrillation and recently developed acute coronary syndrome.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: The antithrombotic strategy for patients with atrial fibrillation (AF) and coronary artery disease following percutaneous coronary intervention is shifting towards less intensive. Nevertheless, for patients with AF and acute coronary syndrome (ACS), an optimal antithrombotic strategy is yet to be established.
Methods And Results: We conducted a multi-center cohort study involving 146 Japanese centers that had prospectively registered 460 patients with AF and ACS followed for 2 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!